## Kazuko Sakata

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/722125/publications.pdf

Version: 2024-02-01

29 papers 2,662 citations

304743 22 h-index 27 g-index

29 all docs 29 docs citations

times ranked

29

3870 citing authors

#	Article	IF	CITATIONS
1	ER stress associated TXNIP-NLRP3 inflammasome activation in hippocampus of human Alzheimer's disease. Neurochemistry International, 2021, 148, 105104.	3.8	33
2	BDNF deficiency and enriched environment treatment affect neurotransmitter gene expression differently across ages. Journal of Neurochemistry, 2020, 154, 41-55.	3.9	23
3	Thioredoxin-Interacting Protein (TXNIP) Associated NLRP3 Inflammasome Activation in Human Alzheimer's Disease Brain. Journal of Alzheimer's Disease, 2019, 68, 255-265.	2.6	77
4	The effect of enriched environment across ages: A study of anhedonia and BDNF gene induction. Genes, Brain and Behavior, 2018, 17, e12485.	2.2	13
5	Hsp90 inhibitor induces nuclear translocation of HSF1 predominantly in hippocampal CA1 region. Molecular Psychiatry, 2017, 22, 935-935.	7.9	O
6	Promoter <scp>IV</scp> â€ <scp>BDNF</scp> deficiency disturbs cholinergic gene expression of <scp>CHRNA</scp> 5, <scp>CHRM</scp> 2, and <scp>CHRM</scp> 5: effects of drug and environmental treatments. Journal of Neurochemistry, 2017, 143, 49-64.	3.9	12
7	A CNS-permeable Hsp90 inhibitor rescues synaptic dysfunction and memory loss in APP-overexpressing Alzheimer's mouse model via an HSF1-mediated mechanism. Molecular Psychiatry, 2017, 22, 990-1001.	7.9	40
8	Bidirectional interplay of HSF1 degradation and UPR activation promotes tau hyperphosphorylation. PLoS Genetics, 2017, 13, e1006849.	3.5	39
9	Antidepressive and BDNF effects of enriched environment treatment across ages in mice lacking BDNF expression through promoter IV. Translational Psychiatry, 2016, 6, e896-e896.	4.8	33
10	Hsp90 Chaperone Inhibitor 17-AAG Attenuates A $\hat{I}^2$ -Induced Synaptic Toxicity and Memory Impairment. Journal of Neuroscience, 2014, 34, 2464-2470.	3.6	102
11	Lack of BDNF expression through promoter IV disturbs expression of monoamine genes in the frontal cortex and hippocampus. Neuroscience, 2014, 260, 265-275.	2.3	47
12	Effects of antidepressant treatment on mice lacking brainâ€derived neurotrophic factor expression through promoter <scp>IV</scp> . European Journal of Neuroscience, 2013, 37, 1863-1874.	2.6	22
13	Role of activity-dependent BDNF expression in hippocampal–prefrontal cortical regulation of behavioral perseverance. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 15103-15108.	7.1	116
14	BDNF may play a differential role in the protective effect of the mGluR2/3 agonist LY379268 on striatal projection neurons in R6/2 Huntington's disease mice. Brain Research, 2012, 1473, 161-172.	2.2	29
15	A key mechanism underlying sensory experience-dependent maturation of neocortical GABAergic circuits in vivo. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 12131-12136.	7.1	77
16	Enriched environment treatment reverses depression-like behavior and restores reduced hippocampal neurogenesis and protein levels of brain-derived neurotrophic factor in mice lacking its expression through promoter IV. Translational Psychiatry, 2011, 1, e40-e40.	4.8	71
17	Lack of promoter IVâ€driven BDNF transcription results in depressionâ€like behavior. Genes, Brain and Behavior, 2010, 9, 712-721.	2.2	85
18	Critical role of promoter IV-driven BDNF transcription in GABAergic transmission and synaptic plasticity in the prefrontal cortex. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 5942-5947.	7.1	183

#	Article	IF	CITATIONS
19	NT-3 facilitates hippocampal plasticity and learning and memory by regulating neurogenesis. Learning and Memory, 2006, 13, 307-315.	1.3	158
20	Altered Synapse Formation in the Adult Somatosensory Cortex of Brain-Derived Neurotrophic Factor Heterozygote Mice. Journal of Neuroscience, 2004, 24, 2394-2400.	3.6	95
21	Cleavage of proBDNF by tPA/Plasmin Is Essential for Long-Term Hippocampal Plasticity. Science, 2004, 306, 487-491.	12.6	1,014
22	Cerebellar Deficits and Hyperactivity in Mice Lacking Smad4. Journal of Biological Chemistry, 2003, 278, 42313-42320.	3.4	60
23	Cloning of a lymphatic peptide/histidine transporter. Biochemical Journal, 2001, 356, 53-60.	3.7	117
24	Cloning of a lymphatic peptide/histidine transporter. Biochemical Journal, 2001, 356, 53.	3.7	78
25	Activated cAMP-response Element-binding Protein Regulates Neuronal Expression of Presenilin-1. Journal of Biological Chemistry, 2001, 276, 9688-9698.	3.4	42
26	Cloning of a bovine orphan transporter and its short splicing variant. FEBS Letters, 1999, 443, 267-270.	2.8	10
27	Characterization of glycine release mediated by glycine transporter 1 stably expressed in HEK-293 cells. Molecular Brain Research, 1997, 49, 89-94.	2.3	30
28	Expression pattern of messenger RNAs for prostanoid receptors in glial cell cultures. Brain Research, 1996, 707, 282-287.	2.2	56
29	Stimulation of Cyclic AMP Formation by Pituitary Adenylate Cyclase-Activating Polypeptide Is Attenuated by Glutamate in Rat Brain Slices. The Japanese Journal of Pharmacology, 1995, 67, 399-402.	1.2	O